Novo Nordisk CEO on Catalent, Ozempic and Wegovy

Novo Owner’s CEO on Obesity Sales Boom, Catalent DealПодробнее

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B CompanyПодробнее

Novo Nordisk CEO on Wegovy, Ozempic Supplies and PricingПодробнее

Novo Nordisk CEO on Q4 results, soaring demand for Wegovy and OzempicПодробнее

Novo Nordisk CEO on safety concerns associated with off-label use of diabetes drugsПодробнее

Top exec at maker of Ozempic, Wegovy talks surging demandПодробнее

Novo Nordisk CEO talks soaring weight-loss drug demand, Q1 earningsПодробнее

TIME100 Most Influential Companies: Novo NordiskПодробнее

Novo Nordisk (Ozempic)Подробнее

Novo Nordisk CFO discusses 36% surge in sales driven by Wegovy and OzempicПодробнее

Doctors explain how Wegovy and Ozempic work | 60 MinutesПодробнее

Weight-Loss Drugs Ozempic, Wegovy Propel Novo Nordisk Into SpotlightПодробнее

What Novo Nordisk's Ozempic Success Means for DenmarkПодробнее

Novo Nordisk extends curbs on WegovyПодробнее

Bio-pharma services are key to our strategy: Novo Holdings CEOПодробнее

Novo Holdings in major deal to boost Wegovy supply | REUTERSПодробнее

This is what happens when you stop taking OzempicПодробнее

How Novo Nordisk built an empire selling diabetes and weight-loss drugsПодробнее